Becton, Dickinson and Company (NYSE:BDX) Stock Holdings Lowered by Mountain Pacific Investment Advisers LLC

Mountain Pacific Investment Advisers LLC cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 4.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,018 shares of the medical instruments supplier’s stock after selling 200 shares during the period. Mountain Pacific Investment Advisers LLC’s holdings in Becton, Dickinson and Company were worth $969,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Livelsberger Financial Advisory acquired a new stake in Becton, Dickinson and Company during the 4th quarter valued at $27,000. Scarborough Advisors LLC purchased a new stake in Becton, Dickinson and Company in the 4th quarter worth about $32,000. Rise Advisors LLC acquired a new stake in Becton, Dickinson and Company during the 1st quarter worth about $38,000. Opal Wealth Advisors LLC purchased a new position in Becton, Dickinson and Company during the 2nd quarter valued at about $45,000. Finally, Abound Wealth Management grew its stake in Becton, Dickinson and Company by 96.0% during the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after acquiring an additional 96 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on BDX shares. Evercore ISI lifted their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus boosted their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Raymond James cut their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price target for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $282.63.

Becton, Dickinson and Company Trading Up 0.4 %

BDX opened at $238.21 on Thursday. The firm’s fifty day moving average is $236.49 and its two-hundred day moving average is $235.46. The firm has a market cap of $68.84 billion, a PE ratio of 52.47, a price-to-earnings-growth ratio of 1.92 and a beta of 0.42. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $269.52. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating the consensus estimate of $3.31 by $0.19. The company had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.96 earnings per share. Equities research analysts anticipate that Becton, Dickinson and Company will post 13.1 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 30th. Stockholders of record on Monday, September 9th were given a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.60%. The ex-dividend date was Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.